Studies exploring the selective reconstitution of DAPk2 catalytic activity were first to demonstrate the proof-of-concept strategy of restoring tumor suppressive kinase activity by targeted delivery of actively constituted DAPk in the context of an immunokinase fusion protein. This evidence concerns the gene DAPK1 and neoplasm.